[
  {
    "question": "patient with MG what is the most sensitive test:",
    "option_a": "Acetyl choline Ab.",
    "option_b": "Single fiber EMG.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia Gravis (MG) is an autoimmune disease in which antibodies disrupt neuromuscular transmission, leading to fluctuating muscle weakness and fatigability. The diagnosis relies on clinical evaluation and a combination of serological and electrophysiological tests. In MG, autoantibodies are typically directed against the postsynaptic acetylcholine receptors (or, less commonly, against MuSK), reducing receptor availability or impairing receptor function. This results in inefficient neuromuscular transmission. Single fiber electromyography (SFEMG) detects the increased variability (jitter) in neuromuscular transmission, which is reflective of the underlying pathophysiological defect. Patients frequently present with ocular symptoms (ptosis, diplopia) and may progress to generalized weakness. The fluctuating nature of the symptoms, which worsen with activity, is characteristic. SFEMG is particularly useful in detecting subclinical neuromuscular transmission defects even when antibody testing may be inconclusive. Evaluation includes a detailed history and physical exam, serologic testing for acetylcholine receptor antibodies, and electrophysiological studies like repetitive nerve stimulation and SFEMG. Differential diagnoses include Lambert-Eaton myasthenic syndrome and botulism, which, while sharing features of fatigable weakness, differ in their electrophysiological profiles and clinical contexts. Initial treatment involves symptomatic management with acetylcholinesterase inhibitors (e.g., pyridostigmine). Immunomodulatory therapies such as corticosteroids and other immunosuppressants are used for long-term control. Thymectomy has a role in certain cases. In pregnant or lactating patients, pyridostigmine is generally considered safe; however, immunosuppressant choices require careful risk\u2010benefit analysis and multidisciplinary coordination. Option A (Acetylcholine receptor antibody test) has high specificity but is less sensitive than SFEMG, especially in purely ocular MG. Option B (Single fiber EMG) is the most sensitive test available for detecting the neuromuscular transmission defect seen in MG. Options C and D are not provided. 1. SFEMG is considered the gold standard for detecting subtle transmission defects in MG. 2. MG often initially presents with ocular symptoms; early detection can significantly improve management outcomes. Recent guidelines emphasize the high sensitivity of SFEMG in MG diagnosis. Current research is focused on earlier detection and intervention with novel immunomodulatory agents to improve long-term outcomes.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient presented with hx of tingling sensation numbness & paresthesia, small fiber neuropathy. He has pale bands over his nails, what is the diagnosis:",
    "option_a": "Gold.",
    "option_b": "Lead.",
    "option_c": "Arsenic.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Small fiber neuropathy involves damage to small-diameter sensory fibers, presenting with tingling, numbness, and paresthesia. Certain toxins, particularly heavy metals, can result in such a neuropathy, with specific nail changes serving as diagnostic clues. Arsenic poisoning disrupts cellular energy processes and induces oxidative stress, leading to peripheral nerve damage. Additionally, arsenic interferes with nail matrix keratinization, resulting in Mees' lines\u2014transverse, pale or white bands on the nails. The clinical scenario of small fiber neuropathy combined with pale bands (Mees' lines) on the nails strongly suggests arsenic poisoning. This presentation helps differentiate it from other causes of toxic neuropathy, such as lead poisoning, which is typically associated with other distinctive clinical findings. Evaluation includes a thorough exposure history, examination for characteristic nail changes, and confirmation with laboratory testing (urinary arsenic levels). Differential diagnoses include lead poisoning (characterized by Burton's lines on the gingiva) and thallium poisoning, but the nail findings are more consistent with arsenic. Management involves immediate removal from the source of arsenic exposure and initiation of chelation therapy (e.g., dimercaprol or succimer). In pregnant or lactating patients, chelation therapy requires careful agent selection and consultation with specialists, as safety profiles vary; for example, succimer has been used with caution in certain circumstances. Option A (Gold) is not typically associated with small fiber neuropathy or nail changes of this nature. Option B (Lead) more commonly causes Burton\u2019s lines on the gingiva and a different neuropathic pattern. Option C (Arsenic) is correct because it correlates with both small fiber neuropathy and Mees' lines. Option D is not provided. 1. Mees' lines (transverse white bands on nails) are a hallmark of arsenic poisoning. 2. A detailed environmental and occupational history is essential in patients with unexplained small fiber neuropathy. Recent studies stress the importance of early identification of heavy metal poisoning using both clinical signs and laboratory testing. Newer chelation protocols have been developed to minimize long-term neurological deficits while considering maternal-fetal safety in pregnant patients.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of Duchene & his brother has the same disease, what is true:",
    "option_a": "The disease is AD.",
    "option_b": "The heart is rarely involved in this disease.",
    "option_c": "The Mother is carrier.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin gene. In X-linked recessive disorders, females are typically carriers and males are affected. The absence or severe deficiency of dystrophin disrupts the structural stability of muscle fibers, leading to progressive muscle degeneration and replacement by fat and connective tissue. Cardiac muscle is frequently involved, leading to cardiomyopathy. Affected males present in early childhood with progressive muscle weakness, pseudohypertrophy of calf muscles, and, over time, cardiac involvement. A positive family history, such as an affected brother, strongly points to an X-linked pattern, confirming that the mother is most likely a carrier. Diagnosis is based on clinical history, markedly elevated creatine kinase levels, genetic testing for dystrophin mutations, and muscle biopsy when necessary. Differential diagnoses include Becker Muscular Dystrophy, which is less severe and results from mutations that allow production of some functional dystrophin. Management primarily involves corticosteroid therapy to slow muscle degeneration, regular cardiac surveillance with medications like ACE inhibitors or beta-blockers, and comprehensive supportive care (physical therapy, respiratory support). In pregnant or lactating women (particularly carriers), genetic counseling is crucial, and treatment strategies must be tailored to balance maternal benefits with fetal safety. Emerging therapies like exon-skipping and gene editing are under investigation. Option A (The disease is AD) is incorrect as DMD is X-linked recessive. Option B (The heart is rarely involved) is false because cardiac complications are common. Option C (The Mother is carrier) is correct. Option D is not provided. 1. DMD is typically evident in early childhood with a rapid progression of muscle weakness. 2. Regular cardiac evaluation is a critical component of long-term management in DMD. Recent research highlights the potential of gene-modulating therapies, including exon-skipping strategies, to restore dystrophin function. Updated guidelines emphasize early cardiac screening and a multidisciplinary approach to improve outcomes in DMD.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "how to differentiate between the C8 & Ulnar neuropathy:",
    "option_a": "Abnormal SNAP",
    "option_b": "Prolonged F-wave.",
    "option_c": "Digiti minimi weakness",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Differentiating between a C8 radiculopathy and an ulnar neuropathy is essential due to the overlapping clinical presentations in the hand. Nerve conduction studies, particularly the evaluation of sensory nerve action potentials (SNAPs), are key in revealing the site of pathology. In radiculopathy (involving the C8 nerve root), the lesion is proximal to the dorsal root ganglion, resulting in preserved SNAPs since the cell bodies remain intact. In contrast, ulnar neuropathy involves the peripheral nerve, leading to abnormal SNAPs due to direct axonal damage or demyelination. Both conditions can present with motor weakness and sensory disturbances in the medial aspect of the hand. However, the presence of abnormal SNAPs on nerve conduction studies strongly indicates a peripheral lesion (ulnar neuropathy) rather than a radicular one. Diagnosis utilizes detailed history, neurological examination, and electrophysiological studies including nerve conduction studies and electromyography (EMG). Differential diagnoses include median or radial nerve entrapments or other cervical radiculopathies; careful mapping of sensory distributions and comparing conduction study findings are essential to distinguish them. Management is directed by the underlying diagnosis. Ulnar neuropathy is often initially managed conservatively with splinting, activity modification, and physical therapy, with surgical decompression considered if conservative measures fail. In cases of radiculopathy, treatment may include physical therapy and epidural steroid injections. Special considerations during pregnancy include the preferential use of noninvasive diagnostic methods and conservative management to avoid fetal risks. Option A (Abnormal SNAP) is correct because abnormal sensory nerve action potentials indicate a lesion in the peripheral nerve (ulnar neuropathy) rather than a root lesion, where SNAPs are typically preserved. Option B (Prolonged F-wave) may occur in both conditions and is not definitive for differentiation. Option C (Digiti minimi weakness) can be present in both C8 radiculopathy and ulnar neuropathy, making it less useful for distinguishing between the two. Option D is not provided. 1. Normal SNAPs in the face of clinical deficits usually point toward a radiculopathy rather than a peripheral nerve lesion. 2. Electrophysiological studies are indispensable in localizing the lesion accurately when clinical findings overlap. Contemporary guidelines and studies continue to support the use of nerve conduction studies and EMG in the evaluation of upper limb neuropathies. Recent literature reinforces that the preservation of SNAPs is a key finding in radiculopathies, while peripheral nerve lesions demonstrate characteristic conduction abnormalities.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient taking multivitamin, what is involved with sensory neuronopathy:",
    "option_a": "Vit B6",
    "option_b": "Vit B12",
    "option_c": "Vit B1",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Sensory neuronopathy involves damage to the dorsal root ganglia, leading primarily to sensory deficits. Certain vitamins, when taken in excess, have neurotoxic potential. Vitamin B6 (pyridoxine) in supratherapeutic doses is well known to cause a predominantly sensory neuropathy or neuronopathy. Excessive amounts of vitamin B6 can lead to toxicity by damaging the cell bodies of sensory neurons in the dorsal root ganglia. This toxicity disrupts normal neuronal signal propagation, leading to symptoms such as numbness, paresthesias, and at times, ataxia. The fine balance in vitamin B6 homeostasis means that even though it is essential in normal metabolic processes, high doses can be detrimental. Patients who ingest high doses of vitamin B6 (sometimes inadvertently via over\u2010the\u2010counter supplements or multivitamins with supraphysiologic doses) may present with predominantly sensory symptoms \u2013 usually in a stocking-glove distribution. Although the deficiency of other B vitamins (like B12 or B1) can cause neurologic symptoms, their clinical presentations differ in distribution and accompanying signs. Diagnosis involves a detailed history (including supplement usage) and neurologic examination. Differential diagnoses include vitamin B12 deficiency (which causes subacute combined degeneration with both dorsal column and corticospinal tract signs) and thiamine deficiency (leading to conditions such as beriberi or Wernicke\u2019s encephalopathy). Electrophysiological studies (nerve conduction tests) may help differentiate toxic neuronopathies from other causes. The cornerstone of management is discontinuation of the offending agent (excess vitamin B6). Supportive care and symptomatic treatment, including physical therapy, are important. Current guidelines recommend avoiding doses exceeding the recommended dietary allowance (RDA) to prevent toxicity. In pregnancy and lactation, vitamin doses should strictly adhere to established guidelines to avoid fetal and neonatal risks. Option A (Vit B6) is correct because pyridoxine toxicity is a well-recognized cause of sensory neuronopathy. Option B (Vit B12) is more commonly associated with posterior column dysfunction (subacute combined degeneration) in deficiency states, not toxicity. Option C (Vit B1) is primarily linked to conditions like beriberi and Wernicke\u2019s encephalopathy rather than a sensory neuronopathy. 1. Vitamin B6 toxicity typically presents with predominantly sensory deficits. 2. The toxicity is dose-related, with doses exceeding 200 mg/day often being problematic. 3. Recovery may be gradual after cessation of the vitamin. Recent research reinforces the narrow therapeutic window for vitamin B6 and highlights that the neurotoxicity is reversible in many cases after stopping high-dose pyridoxine. Updated clinical guidelines stress the importance of adhering to RDA levels, especially in populations self-medicating with supplements.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with UL & LL weakness & numbness with bilateral LL edema:",
    "option_a": "POEM.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question describes a patient with both upper and lower limb weakness and numbness, coupled with bilateral lower limb edema. The constellation of neuropathy with peripheral edema is characteristic of POEMS syndrome, a paraneoplastic condition associated with a plasma cell dyscrasia. POEMS syndrome stands for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes. The underlying mechanism involves a plasma cell disorder that leads to the secretion of cytokines, such as vascular endothelial growth factor (VEGF), which increases vascular permeability resulting in edema and contributes to the development of a demyelinating polyneuropathy. Clinically, patients with POEMS syndrome present with a progressive, symmetric polyneuropathy that affects both motor and sensory fibers. The presence of systemic features like edema (especially of the lower extremities), organomegaly, endocrine abnormalities, and skin changes can help distinguish it from other causes of polyneuropathy. Diagnosis is made through a combination of clinical presentation, nerve conduction studies that tend to show a demyelinating process, serum VEGF levels (which are often elevated), and evidence of a monoclonal plasma cell disorder on serum/urine protein studies. Differential diagnoses include chronic inflammatory demyelinating polyneuropathy (CIDP), but the systemic signs (edema, organomegaly, endocrinopathy) favor POEMS syndrome. Management involves treating the underlying plasma cell disorder. For localized disease (solitary plasmacytoma), radiation therapy is the first line, while systemic disease may require chemotherapy, immunomodulatory agents, or autologous stem cell transplantation. In pregnant or lactating women, treatment must balance maternal benefit and fetal safety; radiation is generally contraindicated during pregnancy, and certain chemotherapeutic agents require cautious use. Option A, which refers to 'POEM' (understood as POEMS syndrome), is correct in this context. Other options, though not provided here, would be less appropriate given the unique combination of polyneuropathy and peripheral edema seen in POEMS. 1. POEMS syndrome is frequently misdiagnosed as CIDP if extraneurological signs are overlooked. 2. Elevated VEGF levels are a helpful diagnostic clue. 3. A high index of suspicion is needed when peripheral edema accompanies polyneuropathy. Recent studies have emphasized the diagnostic utility of serum VEGF in POEMS syndrome. Advances in treatment, including the use of novel agents and stem cell transplantation, have improved patient outcomes, but treatment strategies must be tailored to the individual, especially in special populations like pregnant women.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient was sleeping wake up with right UL pain followed by weakness with multiple nerve involvement",
    "option_a": "MMN",
    "option_b": "Personage turner",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical scenario describes a patient who awoke from sleep with acute right upper limb pain followed by weakness affecting multiple nerves. This pattern is classic for Parsonage-Turner syndrome (also known as neuralgic amyotrophy), an acute inflammatory neuropathy primarily affecting the brachial plexus. Parsonage-Turner syndrome is believed to be immune-mediated, often triggered by a viral illness, immunization, or other stressors. The inflammation primarily affects the brachial plexus leading to severe pain that evolves into muscle weakness and, in some cases, atrophy. The exact mechanism is not fully understood, but an autoimmune attack on nerve fibers is implicated. Patients typically report a sudden onset of severe shoulder or upper arm pain, often occurring at night. This pain is then followed by weakness and sometimes sensory changes in the affected limb. The distribution of weakness can involve several nerves/branches of the brachial plexus. Diagnosis is clinical, supported by electromyography (EMG) and nerve conduction studies. Imaging (e.g., MRI) may be used to rule out other causes. Differential diagnoses include Multifocal Motor Neuropathy (MMN), which is usually painless and slowly progressive, and cervical radiculopathy, which often has a different pattern of sensory involvement and may be provoked by neck movements. Initial management centers on pain control using analgesics and neuropathic pain agents. Corticosteroids are sometimes used to reduce inflammation, though their benefit is debated. Physical therapy is critical for optimizing recovery. In pregnancy and lactation, non-pharmacologic pain management and cautious use of medications (avoiding drugs with teratogenic potential) are recommended. Option A (MMN) is incorrect because Multifocal Motor Neuropathy tends to be a gradual, painless, purely motor disorder without acute onset pain. Option B, representing 'Personage Turner' (interpreted as Parsonage-Turner syndrome), correctly describes the clinical scenario with sudden, post-sleep pain followed by weakness involving multiple nerves. 1. Parsonage-Turner syndrome typically begins with intense pain that later gives way to weakness. 2. Recovery can be prolonged, sometimes taking many months with residual deficits. 3. It is important to differentiate this syndrome from cervical radiculopathy and other neuropathies. Recent literature supports a largely supportive management approach with emphasis on pain control and physiotherapy. Studies are ongoing regarding the benefit of corticosteroids and other immunomodulatory treatments, but no consensus has been reached on a standard protocol.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Anti-striatal Antibody in MG indicates:",
    "option_a": "Thymoma.",
    "option_b": "Ocular MG",
    "option_c": "Resistance to steroid therapy.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti-striational antibodies are autoantibodies directed against striated muscle proteins. In the context of myasthenia gravis (MG), their presence is particularly associated with a more generalized form of the disease and has been linked with thymoma. In thymoma-associated MG, abnormal thymic epithelial cells may trigger an autoimmune response that produces both antibodies against the acetylcholine receptor (AChR) and against striated muscle proteins (e.g., titin, ryanodine receptor). These anti-striational antibodies indicate a broader autoimmune reaction that is often linked to the presence of a thymoma. Patients with MG who have anti-striational antibodies typically present with a more severe, generalized form of the disease rather than an ocular-limited variant. They are more likely to have thymic abnormalities, such as a thymoma, which can influence both prognosis and management. Diagnosis of MG involves clinical evaluation, edrophonium testing in the past (now largely replaced by antibody assays and electrophysiologic studies), and serologic testing for antibodies. When anti-striational antibodies are detected, a CT scan of the chest is recommended to evaluate for a thymoma. Differential diagnoses include ocular MG (which rarely has these antibodies) and other autoimmune neuromuscular junction disorders. Management of MG involves symptomatic treatment with acetylcholinesterase inhibitors (such as pyridostigmine) and immunosuppression (corticosteroids, azathioprine, or mycophenolate mofetil) for more generalized forms. Thymectomy is recommended in patients with thymoma and is increasingly considered in generalized MG even without thymoma. In pregnancy and lactation, pyridostigmine is generally considered safe; corticosteroids remain an option but require careful monitoring, and thymectomy is usually deferred until after delivery unless absolutely indicated. Option A (Thymoma) is correct because anti-striational antibodies are most commonly associated with thymoma in patients with generalized MG. Option B (Ocular MG) is incorrect, as these antibodies are rarely found in ocular-limited forms. Option C (Resistance to steroid therapy) is not supported by evidence that directly links these antibodies with steroid resistance. 1. Anti-striational antibodies serve as a marker for thymoma and a more severe generalized form of MG. 2. Their presence should prompt imaging of the chest to rule out a thymoma. 3. Management of MG is tailored based on antibody profile and thymic pathology. Recent guidelines emphasize the importance of antibody profiling in MG to guide management. The association between anti-striational antibodies and thymoma has been well established, and current research continues to explore the role of early thymectomy and targeted immunotherapy in improving outcomes in these patients.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with UL numbness, she has loss of pain, she is burning her hands. What is the diagnosis:",
    "option_a": "Syringomyelia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Syringomyelia is characterized by the development of a fluid-filled cavity (syrinx) within the spinal cord, most commonly in the cervical region. This condition typically presents with a 'cape-like' distribution of sensory loss, particularly affecting pain and temperature sensations while sparing proprioception and light touch. In syringomyelia, the formation and expansion of a syrinx within the spinal cord compress the decussating fibers of the spinothalamic tract in the anterior commissure. This disruption leads to bilateral loss of pain and temperature sensation in the upper extremities, which may manifest as numbness and dysesthetic burning sensations. The clinical presentation of a patient with upper limb numbness, selective loss of pain sensation, and associated burning hands aligns with the classic features of syringomyelia. The 'cape distribution' of sensory deficits is a hallmark of this condition and helps differentiate it from other neurological disorders. The diagnosis of syringomyelia is primarily confirmed through magnetic resonance imaging (MRI) of the cervical spine, which reveals the presence and extent of the syrinx. Differential diagnoses include central cord syndrome (often post-traumatic), peripheral neuropathies, and demyelinating disorders. A thorough neurological exam combined with imaging studies is essential to exclude other causes of dissociated sensory loss. Management depends on the severity and progression of the neurological deficits. Observation with serial imaging may be appropriate for stable cases. When progressive neurological decline is evident, neurosurgical intervention such as decompression or shunting may be indicated. In pregnancy, careful multidisciplinary management is necessary: conservative management is preferred if the condition is stable, while any surgical intervention must consider fetal safety, typically delaying non-emergent procedures until postpartum if possible. For lactating patients, medications such as gabapentinoids may be used cautiously after evaluating their risk\u2013benefit profile. The option 'Syringomyelia' is the best match given the presentation of selective upper limb numbness with loss of pain sensation and burning dysesthesias in the hands. Despite the incompleteness of other options, the clinical details provided strongly support syringomyelia as the correct answer. A 'cape-like' distribution of impaired pain and temperature sensation with preserved proprioception is highly suggestive of a central lesion such as syringomyelia. Early imaging is critical for diagnosis, and management decisions, including potential surgical decompression, should be made in consultation with neurosurgery and, in cases of pregnancy, with obstetric care. Current guidelines underscore the importance of early MRI in cases of suspected syringomyelia. Recent studies emphasize minimally invasive surgical techniques when intervention is warranted. The management of syringomyelia in pregnant or lactating patients must always balance the risks and benefits, encouraging conservative treatment when possible while closely monitoring for any neurological progression.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "which of the following paired muscles supplied by L5:",
    "option_a": "tibialis anterior & tibialis posterior.",
    "option_b": "Tibialis anterior & abductor hallucis longus.",
    "option_c": "Tibialis anterior & adductor digiti minimi",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question tests the understanding of lower limb myotomes, specifically muscles with significant L5 nerve root contributions. Tibialis anterior is classically recognized as an L5 muscle, responsible for dorsiflexion, while tibialis posterior, although receiving dual innervation (L4\u2013L5), has a significant L5 component. The goal is to identify a pair in which both muscles have a notable L5 input. Compression or dysfunction of the L5 nerve root (commonly due to disc herniation at L4\u2013L5 or foraminal stenosis) may result in muscle weakness, particularly noted in the tibialis anterior. Even though tibialis posterior is innervated by the tibial nerve with contributions mostly from L4 and L5, its L5 component makes it relevant. These nerve root compressions lead to characteristic clinical findings such as foot drop and altered gait. Patients with L5 radiculopathy typically exhibit weakness in dorsiflexion of the foot and toe extension (usually tested with the extensor hallucis longus, not listed here). Examination often reveals diminished strength in the tibialis anterior and, in some cases, a subtle weakness in tibialis posterior. Other muscles (like abductor hallucis and adductor digiti minimi) are innervated predominantly by S1 or S2, respectively, and are less relevant in L5 pathology. Evaluation of a suspected L5 radiculopathy involves a detailed neurological exam focusing on myotomal strength (notably dorsiflexion via tibialis anterior), reflex testing, and imaging studies such as MRI to look for disc herniation or foraminal narrowing. Electrophysiological studies (EMG/NCS) can further localize the lesion. Management of L5 radiculopathy includes initial conservative treatment with physical therapy, non-steroidal anti-inflammatory drugs (with caution in pregnancy and lactation; NSAIDs are generally avoided especially in the third trimester and during lactation alternative analgesics may be chosen), and epidural steroid injections if needed. In refractory cases, surgical decompression may be indicated. For pregnant patients, treatment is tailored to minimize fetal exposure, typically leaning towards physical therapy and carefully selected injections under expert guidance. Option A is comprised of tibialis anterior and tibialis posterior. Tibialis anterior is the prototypical L5 muscle, and tibialis posterior, although it has dual innervation (L4\u2013L5), has a significant L5 contribution, making this pair the best answer. Option B includes abductor hallucis, which is primarily innervated by the medial plantar nerve (predominantly S1) and, therefore, is not consistent with an L5 distribution. Option C includes adductor digiti minimi, a muscle that is typically supplied by nerves with S2\u2013S3 contributions (or, in the hand, by the ulnar nerve), making it inappropriate for an L5 pairing. \u2022 The tibialis anterior is the key muscle to test for L5 function (dorsiflexion weakness, foot drop).  \u2022 While tibialis posterior is not the primary muscle tested for L5 radiculopathy, its L5 component makes it the best available pair in these options.  \u2022 Abductor hallucis and adductor digiti minimi are more reflective of S1 and S2 innervation, respectively. Recent clinical guidelines underscore the importance of a targeted neurological exam when assessing radiculopathies. Conservative management remains first-line, with surgical interventions reserved for cases that do not respond to non-operative measures. Special considerations in pregnancy and lactation ensure that treatment modalities are adapted to minimize risk to the fetus or infant, with particular caution regarding medication use.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient presented with dysphagia, tongue fasciculation, exaggerated jaw reflex for 18 months, with other neuro exam normal, No NCS in the question:",
    "option_a": "progressive bulbar palsy",
    "option_b": "Bulbar onset ALS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Progressive bulbar palsy (PBP) is a clinical phenotype of motor neuron disease in which the degeneration is predominantly confined to the bulbar region. It is characterized by dysphagia, dysarthria, and tongue fasciculations (a lower motor neuron sign) along with signs of upper motor neuron involvement, such as an exaggerated jaw reflex. ALS and its variants, including PBP, involve degeneration of both upper and lower motor neurons. In PBP, the pathology affects the brainstem motor nuclei responsible for bulbar functions. The loss of lower motor neurons leads to fasciculations and weakness while the involvement of upper motor neurons produces brisk reflexes like an exaggerated jaw jerk. The patient\u2019s 18-month history of dysphagia, tongue fasciculations, and an exaggerated jaw reflex\u2014without limb involvement\u2014is typical of an isolated bulbar syndrome. This pattern is most consistent with progressive bulbar palsy, where symptoms remain confined to the bulbar region for a prolonged period. The diagnosis is primarily clinical. In motor neuron disease, electromyography (EMG) is used to demonstrate widespread denervation, while nerve conduction studies are usually normal. Differential diagnoses include myasthenia gravis, brainstem lesions, or stroke; however, the combination of upper and lower motor neuron signs specifically localized to the bulbar region supports PBP. Management is focused on symptomatic and supportive care. This includes nutritional support (e.g., implementation of a gastrostomy tube if needed), speech and swallow therapy, and respiratory monitoring. Riluzole is the only FDA-approved disease-modifying treatment, but its use in pregnant or lactating women must be carefully considered with risk\u2013benefit discussions, as its safety profile in these populations is not fully established. Multidisciplinary care is essential to optimize quality of life. Option A, Progressive Bulbar Palsy, is the most accurate given the clinical scenario. The patient\u2019s prolonged isolated bulbar involvement (18 months) is characteristic of PBP rather than a more rapidly progressive bulbar onset ALS that typically spreads to other regions sooner. Although some clinicians may use the term 'bulbar onset ALS' interchangeably, the duration and isolation of symptoms favor the PBP categorization. \u2022 An isolated bulbar presentation with both UMN (exaggerated jaw reflex) and LMN (tongue fasciculations) signs over a prolonged period suggests PBP. \n\u2022 Early recognition and multidisciplinary supportive care are crucial to managing complications such as dysphagia and respiratory compromise. \n\u2022 Always consider treatment implications in special populations, including pregnant or lactating patients, when planning interventions. Recent guidelines emphasize a multidisciplinary approach and early symptomatic management in motor neuron diseases. Although riluzole is standard, research into newer neuroprotective agents continues. There's also increasing attention on the quality of life improvements through speech, nutritional, and respiratory support. Current evidence supports the use of tailored interventions, especially when managing vulnerable populations like pregnant or lactating patients.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "40 years old male patient with left arm weakness, there was thenar & hypothenar atrophy, there was fasciculation, sensory normal:",
    "option_a": "MMN",
    "option_b": "Limb onset ALS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune-mediated disorder that causes asymmetric, predominantly distal upper limb weakness with conduction block on nerve conduction studies. It is characterized by pure motor involvement with preserved sensory function, making it a key differential in cases presenting with isolated motor deficits. MMN is thought to be mediated by an autoimmune response, often associated with anti-GM1 antibodies, which leads to focal demyelination and conduction block of motor nerves. This results in muscle weakness and atrophy, especially in the distal muscles such as the thenar and hypothenar groups. Clinically, patients typically present with asymmetric hand weakness, muscle atrophy, and sometimes fasciculations. Despite these motor deficits, sensory examination remains normal. This constellation of findings differentiates MMN from other motor neuron disorders, such as ALS, where upper motor neuron signs and widespread progression may be noted. The diagnostic evaluation includes a detailed neurological exam, nerve conduction studies (which may demonstrate conduction block in motor nerves), and serum antibody tests (for example, anti-GM1). Differential diagnoses include limb-onset ALS (which usually has additional UMN signs) and other inflammatory neuropathies. The first-line treatment for MMN is intravenous immunoglobulin (IVIg), which has been shown to improve motor strength and function. IVIg is considered safe during pregnancy and lactation, making it a preferred option for pregnant or breastfeeding patients. Other immunomodulatory agents may be considered second-line, but they require careful risk-benefit analysis, especially in special populations. Option A (MMN) is consistent with the patient\u2019s presentation of isolated left arm weakness with thenar and hypothenar atrophy, fasciculations, and normal sensory findings. In contrast, limb-onset ALS (Option B) typically demonstrates both upper and lower motor neuron signs; the absence of UMN features in this case supports the diagnosis of MMN. \u2022 In patients with pure motor deficits and normal sensation, always consider MMN, especially if the weakness is asymmetric and involves distal limb muscles. \u2022 Electrophysiological studies showing conduction block are key to diagnosis. \u2022 IVIg is an effective treatment and is safe in pregnancy and lactation. Recent clinical guidelines and studies support the use of IVIg as a first-line therapy in MMN, demonstrating improvement in motor function and quality of life. There remains a strong emphasis on distinguishing MMN from ALS given the vastly different prognoses and treatment responses.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "what is the most common familial gene in ALS:",
    "option_a": "C9ORF72",
    "option_b": "TDP 34",
    "option_c": "SOD1",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "ALS (Amyotrophic Lateral Sclerosis) is a progressive neurodegenerative disorder that affects both the upper and lower motor neurons. About 10% of ALS cases are familial, and within these, certain gene mutations are commonly identified. The C9ORF72 hexanucleotide repeat expansion is recognized as the most frequent genetic abnormality seen in familial ALS. The C9ORF72 mutation leads to a toxic gain-of-function through the abnormal accumulation of RNA foci and dipeptide repeat proteins. These pathogenic processes result in neuronal dysfunction and apoptosis. While other mutations like SOD1 are also implicated in familial ALS, current evidence supports that the C9ORF72 expansion is more commonly encountered in familial cases, often with an overlap with frontotemporal dementia. Patients with familial ALS due to the C9ORF72 mutation typically present with progressive motor weakness and spasticity. In some cases, cognitive and behavioral changes may emerge, consistent with the overlap seen with frontotemporal dementia. A detailed family history and genetic testing are key in these patients. The diagnosis relies on clinical evaluation, electromyography (EMG) to determine motor neuron involvement, and confirmation via genetic testing. Differential diagnoses include sporadic ALS, other neurodegenerative disorders, and conditions mimicking motor neuron disease. A careful family history helps differentiate familial cases. Management is primarily supportive and multidisciplinary. Approved medications like Riluzole and Edaravone may modestly slow disease progression. Genetic counseling is important for familial cases. In the context of pregnancy and lactation, treatment must be individualized, with careful consideration of medication safety and supportive care measures. Option A (C9ORF72) is correct because it identifies the most common familial gene mutation in ALS. Option B refers to TDP-43, an abnormal protein implicated in ALS pathology but not a familial gene mutation. Option C (SOD1) is a well-known familial mutation; however, its prevalence is lower compared to the C9ORF72 expansion in familial cases. 1. Familial ALS represents about 10% of all ALS cases, with C9ORF72 being the most common genetic cause. 2. C9ORF72 mutations can also be associated with frontotemporal dementia. 3. Genetic testing is essential for identification and counseling in familial ALS. Recent research continues to reinforce the role of the C9ORF72 hexanucleotide repeat expansion as a predominant cause of familial ALS. Novel therapies targeting these pathogenic mechanisms are under investigation, and updated guidelines emphasize early genetic counseling and multidisciplinary management.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Male patient developed weakness, ?ptosis CTA image attached:",
    "option_a": "is correct because it corresponds to the diagnosis of MG, which fits the clinical scenario of fluctuating weakness and ptosis, along with imaging suggestive of thymic pathology. Other theoretical options might suggest conditions such as Lambert",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia Gravis (MG) is an autoimmune neuromuscular junction disorder characterized by fluctuating muscle weakness and commonly involves ocular muscles (leading to ptosis and diplopia). The thymus often plays a role in the pathogenesis, making imaging for thymic pathology an integral part of the evaluation. MG results from autoantibodies directed against acetylcholine receptors (or related proteins) at the postsynaptic neuromuscular junction. This antibody-mediated attack impairs neuromuscular transmission, leading to muscle fatigue and weakness that typically worsens with exertion and improves with rest. Thymic abnormalities, such as thymoma or hyperplasia, are frequently observed. Patients usually present with ocular symptoms like ptosis and diplopia, which may be accompanied by generalized weakness. The clinical picture is typically one of fluctuating symptoms that worsen with activity. Imaging studies often reveal thymic pathology supporting the diagnosis. Diagnosis involves a combination of clinical evaluation, serologic testing for anti-acetylcholine receptor antibodies, electrophysiological studies (repetitive nerve stimulation or single-fiber EMG), and pharmacological tests (such as the edrophonium test). Differential diagnoses include Lambert-Eaton Myasthenic Syndrome, motor neuron diseases, and cranial nerve palsies. The first-line management for MG involves symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine). Immunomodulatory therapies, including corticosteroids and other immunosuppressants, are often added for long-term management. Thymectomy is recommended in patients with thymoma and in selected cases without thymoma showing generalized MG. In pregnancy and lactation, pyridostigmine is generally considered safe, but immunosuppressive therapy requires careful risk-benefit assessment. Option A is correct because it corresponds to the diagnosis of MG, which fits the clinical scenario of fluctuating weakness and ptosis, along with imaging suggestive of thymic pathology. Other theoretical options might suggest conditions such as Lambert-Eaton syndrome, motor neuron disease, or muscular dystrophies; however, these do not match the classic presentation of MG defined by ocular involvement and response to therapies. 1. Fluctuating muscle weakness with ocular involvement (ptosis) is a classic presentation of MG. 2. Thymic pathology is commonly associated, making imaging studies relevant. 3. MG typically improves with rest, a critical diagnostic clue. Current clinical guidelines underscore the importance of early diagnosis and prompt management of MG using acetylcholinesterase inhibitors and immunosuppressive therapy. Recent research continues to explore optimal immunomodulatory regimes and the role of thymectomy, including considerations for treatment during pregnancy.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Male patient k/c of diabetic on metformin, and multiple comorbidities (long secinarion and there other medications) he developed anemia with high MCV and neuropathy, I think in exam loss of vibration what is the mechanism of developing this neuropathy:",
    "option_a": "Metformin related (metformin caused B12 DEF)",
    "option_b": "diapetic neuropathy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Vitamin B12 deficiency is a potential adverse effect of long-term metformin therapy in diabetic patients. This deficiency can lead to megaloblastic anemia (characterized by an elevated mean corpuscular volume, MCV) and neurological complications including neuropathy. Metformin interferes with vitamin B12 absorption in the terminal ileum by affecting calcium-dependent uptake mechanisms. Over time, this malabsorption can lead to vitamin B12 deficiency, which is essential for myelin formation. The deficiency causes demyelination, particularly affecting the dorsal columns, leading to sensory deficits like loss of vibration and proprioception. In diabetic patients on metformin, the development of macrocytic anemia along with neuropathy (notably loss of vibration sense) strongly suggests vitamin B12 deficiency rather than diabetic peripheral neuropathy, which typically presents with a different pattern and normal MCV. Assessment includes serum vitamin B12 levels and may be supported by elevated levels of methylmalonic acid and homocysteine. Differential diagnoses include diabetic neuropathy, other nutritional deficiencies, and alcohol-related neuropathies; however, the presence of macrocytic anemia is particularly suggestive of vitamin B12 deficiency. Management involves vitamin B12 supplementation, preferably with intramuscular injections initially if severe, followed by oral supplementation if appropriate. In pregnant and lactating women, vitamin B12 injections are safe and effective. Regular monitoring of vitamin B12 levels in patients on long-term metformin is recommended as part of diabetic care. Option A (Metformin-induced vitamin B12 deficiency) is correct because it accounts for both the macrocytic anemia and the specific neuropathic findings (loss of vibration) in this clinical scenario. Option B (diabetic neuropathy) is less likely given that diabetic neuropathy typically does not present with macrocytosis and has a different clinical pattern. 1. Long-term metformin use is associated with vitamin B12 deficiency; regular monitoring is crucial. 2. Macrocytic anemia in a diabetic patient on metformin should prompt evaluation for B12 levels. 3. Neuropathic deficits with loss of vibration are hallmarks of B12 deficiency-related subacute combined degeneration. Emerging research and current guidelines emphasize routine screening for vitamin B12 deficiency in patients on metformin. This is supported by evidence linking deficiency with both hematologic and neurological complications, underscoring the need for early intervention.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Scenario about Patient with MMN:",
    "option_a": "IVIG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune-mediated neuropathy that is primarily characterized by motor dysfunction without significant sensory loss. The condition typically demonstrates conduction blocks on electrophysiological studies and is notably responsive to immunotherapy. MMN is believed to result from an autoimmune attack that disrupts nerve conduction in motor fibers, leading to focal or multifocal conduction block. This immune-mediated process spares sensory fibers, thereby differentiating it from many other neuropathies. Clinically, MMN often presents with slowly progressive, asymmetric, distal limb weakness that is not accompanied by sensory deficits. The response to immunomodulatory therapy, particularly IVIG, further supports the diagnosis. Electrophysiological studies (nerve conduction studies) are key, demonstrating motor conduction block without sensory involvement. Differential diagnoses include amyotrophic lateral sclerosis (ALS) and chronic inflammatory demyelinating polyneuropathy (CIDP); however, the pure motor involvement and response to IVIG help distinguish MMN. The first-line treatment for MMN is intravenous immunoglobulin (IVIG), which has been shown to improve muscle strength and functionality. Second-line therapies may include immunosuppressive agents such as cyclophosphamide for refractory cases, though these are used less frequently. IVIG is generally considered safe in pregnancy and lactation, making it the preferred option in these scenarios. Option A (IVIG) is correct as it remains the gold standard and first-line therapy for MMN. Given the clinical scenario and the characteristic response to immunomodulatory therapy, other options (though not fully specified) would be less appropriate or effective. 1. MMN is a treatable motor neuropathy with a good response to IVIG. 2. Unlike ALS, MMN presents without significant sensory deficits. 3. IVIG is considered safe during pregnancy and lactation, which is beneficial for affected women of childbearing age. Recent studies and updated guidelines continue to support IVIG as the first-line treatment for MMN. Investigations into additional immunomodulatory treatments are ongoing, particularly for patients who are refractory to IVIG, but current evidence firmly places IVIG at the center of MMN management.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Scenario about Patient with CIDP, treatment:",
    "option_a": "IVIG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated disorder affecting peripheral nerves characterized by progressive or relapsing weakness and sensory dysfunction. The condition is chronic and distinct from acute demyelinating neuropathies like Guillain\u2011Barr\u00e9 syndrome. CIDP involves an autoimmune attack against the myelin sheath of peripheral nerves. T\u2010cells, macrophages, and pathogenic antibodies contribute to demyelination and, in some cases, secondary axonal damage. IVIG works by modulating the immune response, neutralizing pathogenic autoantibodies, and interfering with complement activation, thereby reducing inflammation. Patients typically present with symmetric motor weakness, sensory deficits, and diminished or absent deep tendon reflexes. Disease progression is usually over at least 8 weeks, helping differentiate it from the acute course of Guillain\u2011Barr\u00e9 syndrome. Elevated cerebrospinal fluid protein with normal cell count further supports the diagnosis. Diagnosis relies on clinical evaluation, nerve conduction studies (which show slowed conduction velocities or conduction block), electromyography (EMG), and cerebrospinal fluid analysis. Differential diagnoses include multifocal motor neuropathy, diabetic polyneuropathy, and hereditary neuropathies, which can be differentiated based on clinical course, lab findings, and electrodiagnostic patterns. First\u2010line treatments include IVIG, corticosteroids, and plasma exchange. IVIG is preferred in many cases due to its relatively favorable side effect profile, especially in patients who might have contraindications to steroids. In pregnancy and lactation, IVIG is considered relatively safe; steroids can also be used with careful monitoring, whereas plasma exchange may be reserved for refractory cases. Option A (IVIG) is correct because IVIG is a well\u2010established first\u2010line treatment for CIDP. Other potential options (like steroids or plasmapheresis) are effective as well but were not provided, making IVIG a valid choice. \u2022 CIDP is a treatable cause of chronic progressive or relapsing neuropathy. \u2022 IVIG therapy is not only effective but also has a favorable safety profile. \u2022 Distinguish CIDP from Guillain\u2011Barr\u00e9 syndrome by its slower progression (beyond 4 weeks). Recent guidelines from bodies like the European Federation of Neurological Societies (EFNS) and Peripheral Nerve Society (PNS) continue to support IVIG as a first\u2010line therapy for CIDP. Ongoing research aims to further elucidate optimal dosing strategies and biomarkers for predicting treatment response.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with long ICU stay developed neuropathy/myopathy, management:",
    "option_a": "Physiotherapy and supportive",
    "option_b": "steroid",
    "option_c": "IVIG OR PLEX",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Critical illness polyneuropathy and myopathy (CIP/CIM) are common complications in patients with prolonged ICU stays. These conditions result in diffuse, symmetric weakness which can impede weaning from mechanical ventilation and hinder recovery. The etiology involves systemic inflammatory responses, sepsis, multi-organ failure, and prolonged immobilization. Microvascular changes, metabolic disturbances (such as hyperglycemia), and inflammatory mediators contribute to nerve and muscle dysfunction. Patients typically exhibit generalized weakness, difficulty in weaning from the ventilator, and atrophy after a prolonged ICU stay. Diagnosis is often clinical and supported by electrophysiological studies. The condition distinguishes itself from other neuropathies by its association with critical illness. Diagnosis is clinical, supplemented by nerve conduction studies and electromyography. Differential diagnoses include Guillain\u2011Barr\u00e9 syndrome (which has an acute onset and different clinical course) and myasthenia gravis. History (prolonged ICU stay) and supportive electrophysiological findings help in confirming CIP/CIM. Management is primarily supportive\u2014early mobilization, physical therapy, and rehabilitation are the cornerstones of treatment. There is no proven pharmacological therapy (steroids, IVIG, or plasmapheresis are not indicated). In pregnant or lactating patients with critical illness weakness, physiotherapy and supportive care remain safe and effective interventions, with careful monitoring to balance physical activity and recovery. Option A (Physiotherapy and supportive care) is correct as it remains the mainstay of treatment. Option B (steroids) has not shown benefit and may worsen myopathy in some cases, and Option C (IVIG or plasmapheresis) is not supported by evidence for CIP/CIM. \u2022 Early and aggressive physiotherapy is crucial in ICU-acquired weakness. \u2022 CIP/CIM is common after prolonged critical illness and sepsis. \u2022 Pharmacologic therapies have not been proven effective in altering the course. Recent studies and systematic reviews confirm that no pharmacological interventions reliably alter the disease course for CIP/CIM and that early rehabilitation-based strategies are key to improving outcomes.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Female Patient complaining of hand numbness wakes him from sleep and improve with had to shake dX?",
    "option_a": "CTS",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Carpal Tunnel Syndrome (CTS) is the most common entrapment neuropathy, where the median nerve is compressed as it passes through the carpal tunnel in the wrist. CTS results from increased pressure within the carpal tunnel leading to compression of the median nerve. This can be due to repetitive wrist motions, anatomical variations, pregnancy-related edema, or other systemic conditions such as rheumatoid arthritis. Classic symptoms include numbness, tingling, and pain in the distribution of the median nerve (thumb, index, middle, and radial half of the ring finger) often exacerbated at night. Patients frequently report shaking or flicking their hand to relieve symptoms (the so-called 'flick sign'). Diagnosis is primarily clinical with confirmatory tests such as Tinel\u2019s sign and Phalen\u2019s test. Nerve conduction studies can objectively demonstrate median nerve compression. Differential diagnoses include cervical radiculopathy (which may involve a different nerve root distribution) and other peripheral neuropathies. Initial management of CTS includes wrist splinting (especially at night), activity modification, and NSAIDs for pain relief. Corticosteroid injections are used for moderate symptoms. Surgical decompression is reserved for refractory cases. In pregnant or lactating women, non-invasive management (splinting and activity modification) is highly recommended due to the self-limiting nature of gestational CTS. Option A (Carpal Tunnel Syndrome) is correct. The patient\u2019s nocturnal symptoms and reported relief upon shaking the hand are classic for CTS. Other options, while not provided in detail, would likely not match this clinical picture. \u2022 The \u2018flick sign\u2019 (shaking the hand to relieve symptoms) is highly suggestive of CTS. \u2022 CTS is more common in women, and pregnancy can be a precipitating factor due to fluid retention. \u2022 Early diagnosis and conservative management can prevent progression. Recent research emphasizes the effectiveness of conservative management in mild to moderate CTS and supports the use of ultrasound both as a diagnostic tool and for guiding corticosteroid injections. Updated clinical guidelines advocate for individualized therapy based on symptom severity.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w spasticity and UMN sign, video attached showed tongue fascinations? and atrophy,? Dx?? (https://youtu.be/xuwdvBXcr30)",
    "option_a": "ALS",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects both upper and lower motor neurons, leading to progressive muscle weakness and atrophy. ALS involves degeneration of the corticospinal (upper motor neuron) and anterior horn cells (lower motor neuron). Genetic factors (e.g., mutations in SOD1, C9orf72) and non-genetic factors (oxidative stress, glutamate excitotoxicity) contribute to neuronal death. The combination of these pathologies accounts for the mixed clinical picture. Patients typically present with a combination of upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron signs (fasciculations, muscle atrophy). Bulbar involvement is common, leading to dysarthria, dysphagia, and tongue fasciculations and atrophy\u2014key features in this case. Diagnosis is primarily clinical, supported by electromyography (EMG) showing denervation changes in multiple regions and ruling out mimics via imaging (MRI). Differential diagnoses include primary lateral sclerosis (which shows only UMN signs) and progressive bulbar palsy (predominantly LMN signs). Management of ALS is multidisciplinary. Approved therapies include riluzole and edaravone which modestly slow disease progression. Supportive care\u2014physical therapy, speech therapy, nutritional support, and respiratory care\u2014are essential. In pregnancy and lactation, the use of disease-modifying therapies is controversial (riluzole is category C) and requires a careful risk-benefit analysis, with supportive measures often being emphasized. Option A (ALS) is correct given the combination of UMN signs (spasticity) and LMN signs (tongue fasciculations and atrophy). Other options, not provided here, would not encompass the mixed picture observed in ALS. \u2022 ALS presents with both UMN and LMN findings\u2014this dual involvement is a hallmark of the disease. \u2022 Bulbar symptoms such as tongue fasciculations and atrophy are common in ALS and signify a poor prognosis. \u2022 Early multidisciplinary care can improve quality of life even though there is no cure. Recent guidelines highlight the modest benefits of riluzole and edaravone, with ongoing research into novel neuroprotective agents. Current studies focus on genetic modifiers and personalized medicine approaches in ALS management.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  }
]